Europe Gastroparesis Market
The Europe gastroparesis market includes the consolidated markets for Germany, France, United Kingdom, Italy, Spain, and Rest of Europe. Europe occupies a significant position in the global gastroparesis market and is expected to register robust growth rate over the forecast period. Increasing incidences of gastroparesis coupled with growing research and developments for gastrointestinal conditions are likely to be the major factors driving the growth of the market in the European region. The Rest of Europe in gastroparesis comprises Switzerland, Netherlands, Ireland, Belgium, Denmark, and others. The rising incidence of gastroparesis along with increasing research and development activities are likely to support the growth of the market in these countries. Switzerland, Sweden, and Denmark are emerging as countries performing remarkable scientific innovations in terms of development of biological molecules and drugs. This capability of these countries for new drug development offers lucrative opportunity for growth of the rest of Europe gastroparesis market. Furthermore, aging population coupled with growing prevalence of diabetes are also projected to accelerate the market growth by 2027.
Among all European countries, Spain, Italy, Germany, France, and the UK are most affected due to the increasing number of COVID-19 cases and associated deaths. Resulting to these situations, the regional government announced local restrictions in countries and ordered to follow the lockdown protocols. Growing research activities about adverse drug reaction of anti-emetics in combination with COVID 19 anti-viral drugs is offering conclusion about the impact of COVID-19 pandemic on the gastroparesis market. For instance, according to research European Journal of Gastroenterology and a study published in November 2020, prokinetic and antiemetic agent domperidone could lead to dangerous interaction with antiviral drugs darunavir/cobicistat and lopinavir/ritonavir (which is preferably used in treatment of coronavirus disease) and their co-administration is considered contraindication. Moreover, due to ongoing impact of COVID-19 pandemic, certain trials have been re-scheduled or delayed. Thus, the above-mentioned factor is likely to create negative impact on the growth of market in the Europe.
Strategic insights for the Europe Gastroparesis provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2020 | US$ 1,283.40 Million |
| Market Size by 2027 | US$ 1,683.42 Million |
| Global CAGR (2020 - 2027) | 4.0% |
| Historical Data | 2018-2019 |
| Forecast period | 2021-2027 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe Gastroparesis refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The gastroparesis market in Europe is expected to grow from US$ 1,283.40 million in 2020 to US$ 1,683.42 million by 2027; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027. Advanced computational technologies such as artificial intelligence (AI) and biomedical engineering hold potential to offer promising solutions for the treatment of gastroparesis. The efficacy of gastric electrical stimulation in improving gastric emptying and reducing symptoms severity in patients with diabetes gastroparesis has already been proven. Moreover, several devices have been awarded with the FDA approval for the treatment of this condition. In February 2015, Medtronic received FDA approval for its Enterra gastric neurostimulator device, which is already available in the market for the treatment of gastroparesis. The device won a regulatory approval for its use in the prevention of nausea and vomiting associated with the idiopathic and diabetic gastroparesis. Thus, the growing emphasis on the research pertaining to the gastric electrical stimulation therapy is anticipated to encourage new technology developments in the gastroparesis market, eventually allowing the market players to come up with better alternatives for the existing gastroparesis treatment modalities in the coming years.
The Europe gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The Europe gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The Europe gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the Europe gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the Europe gastroparesis market is segmented into France, Germany, Italy, Spain, UK, and rest of Europe. Germany held the largest market share in 2019.
A few major primary and secondary sources referred to for preparing this report on the gastroparesis market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Allergan Plc; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD.
The Europe Gastroparesis Market is valued at US$ 1,283.40 Million in 2020, it is projected to reach US$ 1,683.42 Million by 2027.
As per our report Europe Gastroparesis Market, the market size is valued at US$ 1,283.40 Million in 2020, projecting it to reach US$ 1,683.42 Million by 2027. This translates to a CAGR of approximately 4.0% during the forecast period.
The Europe Gastroparesis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Gastroparesis Market report:
The Europe Gastroparesis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Gastroparesis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Gastroparesis Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Gastroparesis Market
